|
About Aradigm
Business Overview
Leadership
|
Pioneering Advancements in the Pulmonary
Pharmaceutical Industry
Aradigm's
team represents a rare combination of multidisciplinary expertise and has
experience bringing a variety of pharmaceutical and health care products to
market in the U.S.
and internationally. Members of the Company's Scientific Advisory Board are
among the world's leading experts in pulmonary medicine. Together, this
leadership team is pioneering important advancements in the pulmonary
pharmaceutical industry and positioning Aradigm as a new leader in the
specialty pharmaceutical market.
Executive Management
|


|
|
Igor Gonda,
Ph.D.
President
& Chief Executive Officer
Dr. Gonda has served as President and Chief Executive
Officer since August 2006, and as a director since September
2001. From December 2001 to August 2006, Dr. Gonda was
the Chief Executive Officer and Managing Director of Acrux
Limited, a publicly traded specialty pharmaceutical company
located in Melbourne,
Australia.
From July 2001 to December 2001, Dr. Gonda was our Chief
Scientific Officer and, from October 1995 to July 2001,
was our Vice President, Research and Development. From
February 1992 to September 1995, Dr. Gonda was a Senior
Scientist and Group Leader at Genentech, Inc. leading
inhalation development of products for severe respiratory
disease. Prior to that, Dr. Gonda held academic positions
at the University
of Aston in Birmingham, United Kingdom,
and the University of Sydney, Australia. Dr. Gonda holds
a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry
from Leeds University,
United Kingdom.
Dr. Gonda was the Chairman of our Scientific Advisory
Board until August 2006. |
| |

|

|
| 
|
|
Nancy
Pecota
Chief Financial Officer
Ms. Pecota has more than 20 years of experience in corporate
accounting and operations management. She previously served
as Chief Financial Officer for NuGEN Technologies, Inc.,
a life sciences tools company that provides specialty
reagents to pharmaceutical and diagnostics companies.
Prior to that she served as a financial consultant to
early- and mid-stage life sciences companies, developing
fundable business models and assessing and improving internal
financial preparation and reporting processes. She has
served as Vice President, Finance and Administration at
Signature BioScience, Inc., a venture-backed biopharmaceutical
company; and as Director, Finance and Accounting for ACLARA
BioSciences, Inc., a biotechnology company. Ms. Pecota
holds a Bachelor of Science in Economics from San Jose
State University and was among the executives named in
the San Francisco Business Times "100 Most Influential
Bay Area Business Women" in 2002 and 2003.
|
| |
|
|
| 

|
|
D. Jeffery Grimes, J.D./M.B.A.
Vice
President, Legal Affairs, General Counsel & Secretary
Mr. Grimes has served as our General Counsel & Corporate
Secretary since June 2007. From May 2005 to June 2007,
Mr. Grimes was an attorney in the Trademark & Brands
department at Intel Corporation’s headquarters in
Santa Clara, CA. From May 2002 to January 2005, Mr. Grimes
was Assistant General Counsel at Connetics Corporation,
a publicly-traded specialty pharmaceutical company focused
on dermatology, located in Palo Alto, CA. From February
2000 to April 2002, Mr. Grimes was Vice President, Corporate
Counsel & Secretary of GN ReSound, Inc. and Beltone
Electronics Corporation, both subsidiaries of a Danish-based
multinational leading medical device company for hearing
devices, reporting at various times during his tenure
in Copenhagen, Denmark; Redwood City, CA; and Chicago,
IL. Prior to becoming in-house counsel, Mr. Grimes was
a commercial litigator for seven years. Mr. Grimes holds
J.D./M.B.A. degrees and a B.S. in Finance from University
of Colorado, Boulder. Mr. Grimes is a member of the Biotechnology
Industry Organization – General Counsel Committee.
|
| |

|

|
Board of Directors
Virgil D. Thompson
Chairman of the Board, Aradigm Corporation
Frank H. Barker
Former Group Chairman, Johnson & Johnson
Igor Gonda, Ph.D.
President & Chief Executive Officer, Aradigm Corporation
Dr. John M. Siebert
Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs
Scientific Advisory
Board
Aradigm's Scientific Advisory Board is a highly regarded team
of scientific experts who help the Company with strategic input
into the development of treatments for severe respiratory disease,
hormonal and metabolic disorders, and in pharmaceutical development
and pulmonary drug delivery in general. The group assists the
Company on a variety of issues related to potential product
applications, product development paths and clinical testing.
Peter R.
Byron,
Ph.D.
Medical College
of Virginia, Virginia Commonwealth
University. Area of
expertise: Aerosol Science/ Pharmaceutics
Peter S. Creticos, M.D.
The Johns Hopkins University School of Medicine
Area of expertise: Allergy/Immunology/Asthma
Stephen J. Farr, Ph.D.
Zogenix, Inc. Area of expertise: Pulmonary Delivery/Pharmaceutics
Phyllis Gardner, M.D.
Stanford University. Area of expertise: Clinical Pharmacology/Drug
Development
Michael Konstan,
M.D.
Rainbow Babies and Children’s Hospital. Area of expertise: Pulmonary
Disease/Cystic Fibrosis
Michael Powell, Ph.D.
Sofinnova Ventures. Area of expertise: Drug Development
Adam Wanner, M.D.
University of Miami. Area of expertise: Chronic
Obstructive Pulmonary Disease (COPD)
Martin Wasserman, Ph.D.
Roche, AtheroGenics (retired). Area of expertise: Asthma
Tunde
Otulana , M.D.
Dr. Otulana, a practicing pulmonologist, was the Senior Vice-President,
Development and Chief Medical Officer at Aradigm until Dec 2008.
He had joined Aradigm in October 1997 as the Vice President
of Clinical & Regulatory Affairs.
From 1991 to 1997, Dr. Otulana was a medical officer and clinical
team leader in Pulmonary Drug Products at the Center for Drug
Evaluation and Research of the FDA. He was responsible for or
participated in the FDA review and approval of major asthma
drugs currently marketed in the US as well as major FDA initiatives
in the pulmonary drug area. He obtained his M.D. degree at University
of Ibadan, Nigeria and completed training in Internal Medicine
at the University College Hospital, Ibadan, and in pulmonary
medicine at Papworth Hospital, Cambridge, England and Howard
University Hospital, Washington, DC.
Dr. Otulana served on the FDA's Anesthesiology and Respiratory
Therapy Devices Advisory Committee for 4 years ending November
2005. He serves on the Editorial Board of the Journal of Aerosol
Medicine and he is an Editorial Reviewer for Chest. He is a
member of United Nations Environmental Program (UNEP) Aerosol
Technical Options Committee charged with overseeing the phase-out
of CFCs under the Montreal Protocol. Dr. Otulana is an Associate
Clinical Professor in Pulmonary and Critical Care Medicine,
University of California, Davis, where he teaches and also runs
an outpatient chest clinic. He is an author on many original
scientific publications.
In
addition to this Scientific Advisory Board, the Company also engages other
scientific and medical experts to assist on issues specific to particular
indications and programs.

|